Off to the Races: The Breakthroughs of Immunotherapy
ASH Clinical News Associate Editor David Steensma, MD, reviews The Breakthrough, which traces the evolution of immunotherapy to treat – and potentially cure – cancer.
Have you read any...
Perish to Publish: Repeated Episodes of Peer Rejection During the Publication Process
In adults – sensitive adults, in particular – who consider themselves academics, repeated episodes of peer rejection can have serious emotional repercussions. We (David...
An ASH Annual Meeting Post-Vivum
“So, what did you learn from ASH?” asked my advisor a couple of weeks after I returned from my first American Society of Hematology...
#SHEmatology and #WOMANcology: Encouraging Women to Explore Careers and Leadership in Hematology and Oncology
Over the past 50 years, women in medicine have gained greater representation, with each generation of trainees moving closer to gender parity. The number...
Advice for the Graduating Hematologist
When I was asked to collect some thoughts to share with hematology/oncology trainees upon completion of their fellowship, I thought back on my experiences...
The Superwarfarin Chronicles
Over the past decade, the use of synthetic cannabinoids/marijuana has increased. These products generally consist of plant material sprayed with chemicals that can interact...
The Roadmap Forward in Follicular Lymphoma: Time for a Precision Approach
Over the past two decades, improved diagnostic accuracy and novel therapeutic approaches have resulted in profound improvements in overall survival in patients with follicular...
The Present and Future Multiple Myeloma Landscape
The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
